Norse-Icelandic Skaldic Poetry of the Scandinavian Middle Ages - an electronic edition

This presentation aims to describe an international project to edit the corpus of Old Norse-Icelandic skaldic poetry and to outline some issues related to electronic aspects of the project, both in its organisation and in its publication. Prof. Clunies Ross will outline the nature of the project and the place of the electronic edition. Tarrin Wills will present information relating to the electronic encoding of the corpus. This will include explanation and discussion of issues related to the collation of electronic facsimiles of the manuscripts and the encoding of skaldic verse, in particular, the encoding of the native poetic devices known as 'kenningar' and 'heiti'.Hosted by the Scholarly Text and Imaging Service (SETIS), the University of Sydney Library, and the Research Institute for Humanities and Social Sciences (RIHSS), the University of Sydney

ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries

This review summarizes the last decade of work by the ENIGMA (Enhancing NeuroImaging Genetics through Meta Analysis) Consortium, a global alliance of over 1400 scientists across 43 countries, studying the human brain in health and disease. Building on large-scale genetic studies that discovered the first robustly replicated genetic loci associated with brain metrics, ENIGMA has diversified into over 50 working groups (WGs), pooling worldwide data and expertise to answer fundamental questions in neuroscience, psychiatry, neurology, and genetics. Most ENIGMA WGs focus on specific psychiatric and neurological conditions, other WGs study normal variation due to sex and gender differences, or development and aging; still other WGs develop methodological pipelines and tools to facilitate harmonized analyses of "big data" (i.e., genetic and epigenetic data, multimodal MRI, and electroencephalography data). These international efforts have yielded the largest neuroimaging studies to date in schizophrenia, bipolar disorder, major depressive disorder, post-traumatic stress disorder, substance use disorders, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, autism spectrum disorders, epilepsy, and 22q11.2 deletion syndrome. More recent ENIGMA WGs have formed to study anxiety disorders, suicidal thoughts and behavior, sleep and insomnia, eating disorders, irritability, brain injury, antisocial personality and conduct disorder, and dissociative identity disorder. Here, we summarize the first decade of ENIGMA's activities and ongoing projects, and describe the successes and challenges encountered along the way. We highlight the advantages of collaborative large-scale coordinated data analyses for testing reproducibility and robustness of findings, offering the opportunity to identify brain systems involved in clinical syndromes across diverse samples and associated genetic, environmental, demographic, cognitive, and psychosocial factors

Long-term effects of adjuvant treatment for breast cancer on carotid plaques and brain perfusion

Purpose: Breast cancer treatment has been associated with vascular pathology. It is unclear if such treatment is also associated with long-term cerebrovascular changes. We studied the association between radiotherapy and chemotherapy with carotid pathology and brain perfusion in breast cancer survivors. Methods: We included 173 breast cancer survivors exposed to radiotherapy and chemotherapy, assessed ± 21.2 years after cancer diagnosis, and 346 age-matched cancer-free women (1:2) selected from the population-based Rotterdam Study. Outcome measures were carotid plaque score, intima-media thickness (IMT), total cerebral blood flow (tCBF), and brain perfusion. Additionally, we investigated the association between inclusion of the carotid artery in the radiation field (no/small/large part), tumor location, and these outcome measures within cancer survivors. Results: Cancer survivors had lower tCBF (− 19.6 ml/min, 95%CI − 37.3;− 1.9) and brain perfusion (− 2.5 ml/min per 100 ml, 95%CI − 4.3;− 0.7) than cancer-free women. No statistically significant group differences were observed regarding plaque score or IMT. Among cancer survivors, a large versus a small part of the carotid artery in the radiation field was associated with a higher IMT (0.05, 95%CI0.01;0.09). Also, survivors with a right-sided tumor had lower left carotid plaque score (− 0.31, 95%CI − 0.60;− 0.02) and higher brain perfusion (3.5 ml/min per 100 ml, 95%CI 0.7;6.2) than those with a left-sided tumor. Conclusions: On average two decades post-diagnosis, breast cancer survivors had lower tCBF and brain perfusion than cancer-free women. Also, survivors with a larger area of the carotid artery within the radiation field had a larger IMT. Future studies should confirm if these cerebrovascular changes underlie the frequently observed cognitive problems in cancer survivors

Consensusverklaring voor de toepassing van rTMS bij depressie in Nederland en België [Consensus statement on the application of rTMS in depression in the Netherlands and Belgium]

Achtergrond: Sinds 2017 komt rTMS (repetitieve transcraniële magnetische hersenstimulatie) voor vergoeding in aanmerking voor de behandeling van therapieresistente depressie in de specialistische ggz in Nederland. Doel: Een aanzet geven voor een richtlijn in Nederland en België voor de veilige en effectieve toepassing van rTMS bij de behandeling van depressie. Methode: Formuleren van adviezen inzake de implementatie van rTMS als behandeling van depressie, op basis van literatuuronderzoek, bestaande richtlijnen en consensus van rtms-experts. Alle beschikbare evidentie werd gewogen en besproken door alle auteurs en op basis van consensus werden aanbevelingen gevormd. Resultaten: rTMS gericht op de dorsolaterale prefrontale cortex (DLPFC) dient als eerste keuze gezien te worden bij de behandeling van depressie, gebruikmakend van hoogfrequente rTMS (links), of als alternatief laagfrequente rTMS (rechts). Stimulatieprotocollen dienen gebruik te maken van meer dan 1000 pulsen per sessie, met gemiddeld 20-30 sessies, 2-5 sessies per week. Contra-indicaties voor rTMS zijn epilepsie, intracraniale aanwezigheid van (magnetiseerbare) metalen, pacemakers en cochleair implantaat. Conclusie: rTMS is een effectieve en veilige methode bij de behandeling van depressie, mits uitgevoerd door bekwame professionals

Consensusverklaring voor de toepassing van rTMS bij depressie in Nederland en België [Consensus statement on the application of rTMS in depression in the Netherlands and Belgium]

Item does not contain fulltextAchtergrond: Sinds 2017 komt rTMS (repetitieve transcraniële magnetische hersenstimulatie) voor vergoeding in aanmerking voor de behandeling van therapieresistente depressie in de specialistische ggz in Nederland. Doel: Een aanzet geven voor een richtlijn in Nederland en België voor de veilige en effectieve toepassing van rTMS bij de behandeling van depressie. Methode: Formuleren van adviezen inzake de implementatie van rTMS als behandeling van depressie, op basis van literatuuronderzoek, bestaande richtlijnen en consensus van rtms-experts. Alle beschikbare evidentie werd gewogen en besproken door alle auteurs en op basis van consensus werden aanbevelingen gevormd. Resultaten: rTMS gericht op de dorsolaterale prefrontale cortex (DLPFC) dient als eerste keuze gezien te worden bij de behandeling van depressie, gebruikmakend van hoogfrequente rTMS (links), of als alternatief laagfrequente rTMS (rechts). Stimulatieprotocollen dienen gebruik te maken van meer dan 1000 pulsen per sessie, met gemiddeld 20-30 sessies, 2-5 sessies per week. Contra-indicaties voor rTMS zijn epilepsie, intracraniale aanwezigheid van (magnetiseerbare) metalen, pacemakers en cochleair implantaat. Conclusie: rTMS is een effectieve en veilige methode bij de behandeling van depressie, mits uitgevoerd door bekwame professionals.10 p

Acute effects of passive muscle stretching on vertical jump performance

BACKGROUND: Survivors of Hodgkin's lymphoma are at increased risk for treatment-related subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late 1980s, on the long-term risk of a second cancer remains unknown. METHODS: We enrolled 3905 persons in the Netherlands who had survived for at least 5 years after the initiation of treatment for Hodgkin's lymphoma. Patients had received treatment between 1965 and 2000, when they were 15 to 50 years of age. We compared the risk of a second cancer among these patients with the risk that was expected on the basis of cancer incidence in the general population. Treatment-specific risks were compared within the cohort. RESULTS: With a median follow-up of 19.1 years, 1055 second cancers were diagnosed in 908 patients, resulting in a standardized incidence ratio (SIR) of 4.6 (95% confidence interval [CI], 4.3 to 4.9) in the study cohort as compared with the general population. The risk was still elevated 35 years or more after treatment (SIR, 3.9; 95% CI, 2.8 to 5.4), and the cumulative incidence of a second cancer in the study cohort at 40 years was 48.5% (95% CI, 45.4 to 51.5). The cumulative incidence of second solid cancers did not differ according to study period (1965-1976, 1977-1988, or 1989-2000) (P=0.71 for heterogeneity). Although the risk of breast cancer was lower among patients who were treated with supradiaphragmatic-field radiotherapy not including the axilla than among those who were exposed to mantle-field irradiation (hazard ratio, 0.37; 95% CI, 0.19 to 0.72), the risk of breast cancer was not lower among patients treated in the 1989-2000 study period than among those treated in the two earlier periods. A cumulative procarbazine dose of 4.3 g or more per square meter of body-surface area (which has been associated with premature menopause) was associated with a significantly lower risk of breast cancer (hazard ratio for the comparison with no chemotherapy, 0.57; 95% CI, 0.39 to 0.84) but a higher risk of gastrointestinal cancer (hazard ratio, 2.70; 95% CI, 1.69 to 4.30). CONCLUSIONS: The risk of second solid cancers did not appear to be lower among patients treated in the most recent calendar period studied (1989-2000) than among those treated in earlier periods. The awareness of an increased risk of second cancer remains crucial for survivors of Hodgkin's lymphoma. (Funded by the Dutch Cancer Society.)